Nanoform Partners with Revio Therapeutics
Nanoform Finland Plc announced a partnership with Revio Therapeutics to co-develop and commercialize GLIORA, a nano-formulated combination of olaparib and temozolomide.
The treatment is a locally-administered, long-acting, thermo-responsive hydrogel for high-grade glioma, a fast-growing and aggressive type of brain tumor.
- Olaparib (Lynparza) was originally developed by AstraZeneca Plc.
- Temozolomide (Temodar) was originally developed by Merck & Company Inc.
Nanoform Finland Plc is a medicine performance-enhancing company.
Author's summary: Nanoform partners with Revio Therapeutics.